MedTrace Logo

Growth Hormone During Fasting.Signaltransduktion in Muscle and Adipose Tissue and Changes in Intrahepatic Lipid Content

NCT00476879 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2008-08-12

No results posted yet for this study

Summary

The purpose of this study is to examine the effects of growth hormone during fasting in healthy lean men.

Conditions

Interventions

DRUG

Somatropin and pegvisomant

Somatropin are given intravenous, 0.5mg pegvisomant are given subcutaneous, 15 mg NaCl are given subcutaneous, 2 ml

Sponsors & Collaborators

  • Aarhus University Hospital

    collaborator OTHER

  • Pfizer

    collaborator INDUSTRY

  • University of Aarhus

    lead OTHER

Principal Investigators

  • Louise Moller, MD · Medical department M, Aarhus Sygehus, Norrebrogade 44, 8000 Aarhus, Denmark

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
40 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2006-08-31
Primary Completion
2007-11-30
Completion
2008-06-30

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00476879 on ClinicalTrials.gov